Home  »  Value Stocks   »  How Much Can Pfizer’s Shares Rise...

How Much Can Pfizer’s Shares Rise

For the fourth quarter of 2020, Pfizer’s (PFE) revenue was higher than the projections of analysts, and adjusted earnings per share dropped short of the expected 12.5 percent to $0.42.

The revenue of the company beat consensus by 1.8 percent, touching $11.68 billion. The figure fell by 3.7 percent relative to the third quarter and declined by 11.8 percent year-on-year.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Full-year 2020 revenues from Pfizer grew by 2% year-on-year to $41.9 billion and adjusted EPS increased by 16% year-on-year to $2.22.

In the reporting period, Pfizer’s oncology business segment led the revenue growth, with a rise of 23 percent year-on-year, powered by Ibrance’s improved revenues (+23 percent year-on-year) due to successful penetration into the CDK and Inlyta segments (+42 percent year-on-year).

Revenue rose by 17 percent year-on-year in the vaccine category. As a result of increased demand in Europe and public procurement in the United States for pediatrics, the blockbuster Prevnar 13/Prevenar 13 continues to demonstrate promising momentum (+11 percent year-on-year). The segment’s revenue growth is also driven by the start of sales of COVID-19’s BNT162b2 vaccine, which produced $154 million in revenue after receiving the EUA in December.

The earnings of its Upjohn subsidiary are no longer included in Pfizer, since it merged with Mylan (MYL) in the fourth quarter to form a separate firm, Viatris (VTRS). Pfizer completed its market focus on the field of biopharmaceuticals with this. These initiatives should contribute, according to the company’s strategy, to an increase in revenue growth and return on equity.

The management of Pfizer has revised its 2021 financial outlook and predicts revenue in the range of $59.4-61.4 billion (+44% YoY) with adjusted EPS in the range of $3.1-3.2 (+42% YoY). The projection recognizes the future contract with an IBT margin of 20 percent for the procurement of the COVID-19 BNT162b2 vaccine with a revenue increase of more than $15 billion.

Although another $5.3 billion is provided for this task, Pfizer does not yet plan to restart its equity repurchase scheme.

We take a favorable view of the Pfizer study, recognizing the positive trends of biopharmaceutical sales and the optimistic outlook for 2021. In the “Market Perform” rating, we lift the target price of PFE shares to $46 and retain the “Buy” recommendation.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.